Norgine Limited was founded in 1906 and is based in Harefield, the United Kingdom with regional offices in Tunisia and Saudi Arabia. It has manufacturing sites in Dreux, France; and Hengoed, the United Kingdom. The company has subsidiaries in the United Kingdom, France, Germany, Belgium, the Netherlands, Denmark, Switzerland, Austria, Italy, and Spain, as well as in Australia, and South Africa. Norgine Limited is a subsidiary of Norgine Europe B.V. Norgine Limited, a specialty pharmaceutical company, develops, manufactures, and markets products in the areas of gastroenterology, hepatology, and pain management in Europe. It offers products for the treatment of chronic constipation and faecal impaction, bowel preparation prior to colonoscopy, ulcerative colitis, Crohn's disease, duodenal and benign gastric ulcers, traveler’s diarrhoea, and pain, as well as provides antitussive medications and products for the relief of smooth muscle spasm. The company also provides assistance in the development and launch of pharmaceutical products for companies.

Semafore Pharmaceuticals is signaling its arrival on the oncology drug making scene. The development-stage drug discovery company is targeting the PI3K cell signaling pathways to create anti-cancer drugs. Its PI3K Inhibitors induce the death of cancerous cells in the treatment of tumors and could potentially treat brain, lung, and hematological cancers. Once administered, its lead candidate SF1126 attacks proteins expressed in tumors, but ignores healthy cells. Semafore has brought on a consulting firm to help shepherd SF1126 through its next stage of development.

Unigene Laboratories, Inc. company was founded in 1980 and is based in Boonton, New Jersey. Unigene Laboratories, Inc., a biopharmaceutical company, engages in the research, production, and delivery of peptides for medical use primarily in the United States. The company focuses on the development of calcitonin and other peptide products for the treatment of osteoporosis and other indications, including nasal and oral calcitonin, and oral parathyroid hormone (PTH). It offers Fortical, a nasal calcitonin product for the treatment of postmenopausal osteoporosis. Unigene Laboratories has licensing agreements with GlaxoSmithKline to develop an oral formulation of an analog of PTH; Upsher-Smith Laboratories, Inc. to market Fortical; Novartis Pharma AG to manufacture calcitonin; and Shijiazhuang Pharmaceutical Group for research, development, and manufacture of recombinant salmon calcitonin and non-oral PTH.

BioSante Pharmaceuticals, Inc. company was founded in 1996 and is based in Lincolnshire, Illinois. BioSante Pharmaceuticals, Inc., a biopharmaceutical company, develops products for female sexual health, menopause, contraception, and male hypogonadism. It develops calcium phosphate nanotechnology for aesthetic medicine, novel vaccines, and drug delivery. The company's products include LibiGel, a transdermal testosterone gel in Phase III development for the treatment of female sexual dysfunction; Elestrin, a transdermal estradiol (estrogen) gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause; Bio-T-Gel, a transdermal testosterone gel in development for the treatment of hypogonadism, or testosterone deficiency in men; and the Pill-Plus for the treatment of female sexual dysfunction in women using oral or transdermal contraceptives. The company's CaP products in development comprise BioLook, which is facial line filler in development using proprietary CaP technology in the area of aesthetic medicine; BioVant for the treatment of viral and bacterial infections and autoimmune diseases; BioOral, a delivery system using CaP technology for oral/buccal/intranasal administration of proteins and other therapies; and BioAir, a delivery system using CaP technology for inhalable versions of proteins and other therapies.

Janssen has gone totally mental. A US-based arm of Johnson & Johnson'sglobal pharmaceuticals segment, Janssen focuses exclusively on treatments for mental health conditions. Its flagship offering Risperdal combats bipolar mania and schizophrenia, as well as irritability associated with autism. A long-acting injectable version of the drug, called Risperdal Consta, is approved as a treatment for schizophrenia. With its sister company Johnson & Johnson Pharmaceutical Research & Development, the company is working on potential drugs for a range of psychiatric problems, including psychosis, sleep disorders, attention deficit/hyperactivity disorder, depression, and substance abuse.

AVANIR Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Aliso Viejo, California. AVANIR Pharmaceuticals, Inc. focuses on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States and Canada. Its lead product candidate includes Zenviatm, which has completed three Phase III clinical trials for the treatment of pseudobulbar affect; and a Phase III trial for the treatment of patients with diabetic peripheral neuropathic pain. The company also offers Abreva, an over-the-counter product for the treatment of cold sores.

China DongSheng International manufactures nutritional supplements and air purifiers. Founded in 1991 as PaperClip Imaging Software, the company's original business was document management software development. After a 2006 reverse merger with American Sunrise International (the holding company of China-based Jilin Dongsheng Weiye Science & Technology Development Co.), the company changed its name to China DongSheng International and shifted its focus to natural health supplements and purifiers. Now generating the majority of its revenues from its new lines, China DongSheng plans to spin off its PaperClip operations.

Fulcrum Pharma plc is a United Kingdom-based company. The Company is engaged in providing solutions for the development of therapeutic products. It provides regulatory expertise and resource throughout all stages of product development. The Company provides customized pharmacovigilance and risk management solutions. It provides support for product registration, launch and in market maintenance. It operates through eight offices across the United States, Europe and Japan. The Company’s subsidiaries include Fulcrum Pharma (Europe) Limited, Fulcrum Pharma Developments Limited, Quadramed Limited, Unicus Limited and Fulcrum Regulatory Limited.

CEO Samuel Bogoch founded Oncolab shortly after he discovered the technology for detecting anti-malignin antibodies in the 1960s. Oncolab, Inc. company makes the AMAS test, an early warning blood screening test for cancer. The test detects abnormal levels of anti-malignin antibody which may indicate the presence of tumors. It is the first antibody that can be directly related to the survival of cancer patients and can be easily detected even before malignin reaches a detectable level. The test is shipped for free and is administered by doctors, then sent to Oncolab to process the results (for a fee); there are also a handful of lab locations that administer the test.

Goldshield Group plc, through its subsidiaries, engages in the development, marketing, and distribution of pharmaceutical and consumer health products. It offers ethical pharmaceuticals, non-prescription medicines, vitamins, minerals and supplements, and various other healthcare products. The company’s pharmaceutical products comprise Ostex, a glucosamine sulphate for joints; Flexeze for glucosamine; and Flexeze Truefil capsules for joints and connective tissues. Its pharmaceutical products are used for chronic disease areas, including cardiovascular diseases, central nervous system disorders, and musculoskeletal conditions. The company’s consumer health products include Appesat for natural weight loss; LIPObind, a natural weight management supplement; Lubramine, a supplement for joint health; Kamillosan, a breastfeeding product; and Infaderm, a soap-free bubble bath product. Its consumer health products also include joints and mobility, bone health, antioxidants, heart and circulation, digestion and detox, weight management, men’s health, women's health, skin care and beauty, heart and bone health, fitness nutrition, immune boosters, joint health, cardiac health, multi vitamins, pet health, centural specials, anti aging, eye health, and well being products. In addition, the company develops wellbeing villages and resorts; publishes magazines for consumers, as well as sells subscriptions and advertising space; and provides telemarketing and management services. Goldshield Group operates in the United Kingdom, Ireland, North America, and India. The company was founded in 1991 and is headquartered in Croydon, the United Kingdom. As of December 21, 2009, Goldshield Group plc was taken private.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.